SRPT
USDSarepta Therapeutics Inc. Common Stock (DE)
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$15.310
Kõrge
$17.750
Madal
$15.080
Maht
2.09M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
1.7B
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
7.10M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance
Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid Elevidys sales weakness.
Baird Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $15
Baird analyst Brian Skorney maintains Sarepta Therapeutics with a Neutral and lowers the price target from $21 to $15.
Futures tumble after Wall St banks warn of market pullback, Palantir slides
U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.
Sarepta slumps as gene therapy setback adds to drug pipeline woes
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.
Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE
Sarepta announces completion of the confirmatory trial commitment for its ultra-rare disease PMO therapies AMONDYS 45 and VYONDYS 53: While the ESSENCE study did not achieve statistical significance on its primary
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Raises Price Target to $16
Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics with a Neutral and raises the price target from $15 to $16.
Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2025 financial results after the Nasdaq Global Market closes on Monday, Nov. 3, 2025.
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.